Unlocking the Future of Healing: My Journey to Immunotherapy

In January 2023, Daniel Miller began to experience alarming symptoms that would change his life forever. What started as mild abdominal discomfort and persistent bloating quickly escalated, prompting a visit to the emergency room. With significant weight loss and overwhelming fatigue, Daniel was determined to uncover the cause of his distress, leading him down an unexpected path.

Initial Symptoms Prompt Emergency Visit

Daniel’s journey began with a series of unusual signs, including:

• Stomach bloating
• Abdominal pain
• Persistent hunger pangs
• Weight loss and fatigue

These troubling symptoms culminated in a trip to the hospital, where a comprehensive examination was initiated.

Comprehensive Testing and Diagnosis

At the hospital, Daniel underwent an extensive battery of tests. Starting with a CT scan, doctors discovered swollen lymph nodes around his aorta and stomach, which raised concerns. This led to additional evaluations, including:

• MRI
• PET scan
• Lymph node biopsy
• Colonoscopy
• Endoscopy

After a thorough investigation, he received a diagnosis of stage IV pancreatic adenocarcinoma, a grim revelation that would shape his treatment options.

Choosing a Treatment Path: Immunotherapy Over Chemotherapy

Determined to fight his diagnosis, Daniel conducted thorough research on pancreatic cancer treatments. He quickly ruled out chemotherapy, opting instead for immunotherapy. Under the guidance of Dr. Praveen Vashist at Pardee Cancer Center, Daniel underwent genetic testing that revealed he was a suitable candidate for this innovative treatment.

Despite his long-standing battle with psoriatic arthritis, Daniel was willing to make sacrifices for his health. He worked closely with his rheumatologist, who prioritized his cancer treatment, leading to a temporary halt of his biologics.

Dr. Vashist prescribed pembrolizumab (Keytruda), administered via infusion every three weeks. Daniel had a port installed in his chest to facilitate treatment. Thankfully, he experienced minimal side effects, including mild skin rashes and occasional loose stools. He also incorporated ZENPEP pancreatic enzyme capsules into his routine to aid digestion after meals.

Monitoring Progress and Maintaining Hope

As of late January, Daniel completed his 17th infusion, accompanied by a CT scan and blood tests. The results were promising—his tumors were shrinking, and his CA 19-9 levels dramatically decreased from over 2,000 to normal ranges. This positive response to treatment has filled Daniel and his medical team with hope.

While managing his psoriatic arthritis without biologics remains a challenge, Daniel remains optimistic about his ongoing journey. He proudly shares that he is Dr. Vashist’s first pancreatic cancer patient to successfully receive Keytruda, reinforcing his belief in the efficacy of immunotherapy.

Final Thoughts

Daniel’s experience underscores the importance of patient advocacy and informed decision-making in cancer treatment. With continued support and monitoring, he remains hopeful for the future, eager to see how his condition evolves.

For those facing similar challenges, exploring the latest treatments and clinical trials can offer new hope in the fight against cancer. Learn more about available options here.